Koninklijke DSM (NASDAQ:RDSMY) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price target of $21.30 for the company, according to Zacks. Zacks has also assigned Koninklijke DSM an industry rank of 40 out of 265 based on the ratings given to related companies.

Several analysts recently weighed in on RDSMY shares. Zacks Investment Research upgraded shares of Koninklijke DSM from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a report on Thursday, April 20th. Liberum Capital upgraded shares of Koninklijke DSM from a “hold” rating to a “buy” rating in a report on Tuesday, March 28th.

COPYRIGHT VIOLATION NOTICE: This story was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/07/26/zacks-koninklijke-dsm-rdsmy-given-21-30-average-price-target-by-brokerages.html.

Shares of Koninklijke DSM (RDSMY) traded up 0.71% on Wednesday, reaching $18.48. The company had a trading volume of 69,492 shares. The stock has a market capitalization of $12.94 billion and a P/E ratio of 16.59. Koninklijke DSM has a 1-year low of $14.50 and a 1-year high of $18.98. The company’s 50 day moving average price is $18.37 and its 200-day moving average price is $17.35.

About Koninklijke DSM

Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.

Get a free copy of the Zacks research report on Koninklijke DSM (RDSMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.